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In a study involving 13842 women and 113 gynaecologists, liquid-based cytology and HPV testing for detecting cervical cancer were
compared. A total of 1334 women were found to be positive for one or both tests and were invited for colposcopy with biopsy. A
total of 1031 satisfactory biopsies on 1031 women were thereafter collected using a systematic biopsy protocol, which was random
in the colposcopically normal-appearing cervix or directed in the abnormal one. In all, 502 women with negative tests were also
biopsied. A total of 82 histologic high-grade squamous intraepithelial lesion (HSIL) were reported in biopsies, all from the group with
one or both tests positive. Sensitivity and specificity to detect histologic HSIL were 59 and 97% for cytology, and 97 and 92% for HPV.
In total, 14% of reviewed negative cytological preparations associated with histologic HSIL contained no morphologically abnormal
cells despite a positive HPV test. This suggested a theoretical limit for cytology sensitivity. HPV viral load analysis of the 1143 HPV-
positive samples showed a direct relationship between abnormal Pap test frequency and HPV viral load. Thus, not only does the HPV
testing have a greater sensitivity than cytology but the probability of the latter being positive can also be defined as a function of the
associated HPV viral load.
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The Pap test is currently central to the detection of cervical cancer
precursors. Conventional smears, whose utilisation started in the
early 1950s, have been progressively replaced by liquid-based
methods over the past 10 years. Discovery of the role of HPV in the
natural history of cervical cancer and the ability to detect it in
liquid cytology medium are rapidly modifying the standard in
cervical cancer detection. HPV detection is nowadays mainly used
in atypical squamous cells of undetermined significance (ASC-US)
triage. The next step will be the utilisation of combined HPV
testing and cytology to detect cervical cancer and its precursors.
After 50 years of cytology as the sole test in cervical cancer
prevention, new methods are appearing to palliate the Achilles’
heel of cytology, which is sensitivity. Indeed, many reports
(Belinson et al, 1999; Kuhn et al, 2000; Ratnam et al, 2000;
Schiffman et al, 2000; Wright et al, 2000; Clavel et al, 2001;
Kulasingam et al, 2002; Petry et al, 2003) have established a higher
sensitivity for HPV than for cytology, although published results
are not unanimous (de Cremoux et al, 2003). The main study
objective was to confirm the better sensitivity of HPV testing,
especially in the context of routine clinical practice.
Between April 2002, and January 2004, a prospective clinical
study was conducted in order to compare two tests for the
detection of cervical cancer precursors: a liquid-based cytology
preparation, Surepath
s (Tripath Imaging, Burlington, NC, USA)
and a test for high-risk HPV DNA, Hybrid Capture
s II (Digene
Corporation, Gaithersburg, MD, USA). The investigation was
conducted in the laboratory Cytopath based in Geneva, Switzer-
land, a private laboratory member of the Unilabs Group. Cytopath
has used liquid-based cytology since 1996, analysing approxi-
mately 100000 slides per year.
MATERIAL AND METHODS
A target of 15000 cytologic samples was established in the hope of
collecting approximately 250 histologic HSIL, providing adequate
power to estimate the differences, if any, in performance
characteristics between the tests. Women 30 or more years of
age had been favoured for study participation in order to optimise
HSIL collection. Most study participants had been screened yearly
with liquid-based cytology starting at least 5 years before this
study. They were thereby considered to be at low risk for cervical
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ycancer. Recruitment was not from sexually transmitted disease
clinics or other high-risk populations. Study participants were
recruited by 113 gynaecologists from six Swiss cantons (Gene `ve,
Vaud, Neucha ˆtel, Fribourg, Valais and Tessin), most of whom are
in private practice. Participants were given the option of study
participation following a discussion with their gynaecologists of
the risks and benefits of enrolment, and the completion of the
informed consent document. Prior to initiation, the study was
reviewed and approved by the Ethics Committee of the ‘Associa-
tion des Me ´decins du canton de Gene `ve’.
Liquid-based cytology
All cervical samples were taken using the Surepath
s (Tripath
Imaging, Burlington, NC, USA) liquid-based preparation. In
agreement with the manufacturer, the gynaecologists put the
collecting device in the Surepath vial after having performed a
cervical scrape. Cervex Brush
s (CooperSurgical Inc., Trumbull,
CT, USA) was the only provided collecting device. All vials were
sent to the Cytopath Laboratory and prepared according to the
protocol recommended by the manufacturer. A homogenised
fraction of the sample was used to prepare the cytological
preparation with the AutocytePrep
s processor. The residual
cellular material underwent centrifugation and was resuspended
in 500ml distilled water for further HPV testing. In the text, ‘CYTO’
refers to the Surepath
s liquid-based cytology test.
HPV testing
HPV testing was performed at the Bioanalytique-Riotton Labora-
tory (another member of the Unilabs group). Cell suspensions
were stored at 2–81C for up to 1 week before HPV testing. The
HPV DNA assay was performed blind to cytologic and histologic
diagnoses. Specimens were tested for high- and intermediate-risk
HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68) using
the Digene High-Risk HPV DNA Test Hybrid Capture
s II (Digene
Corporation, Gaithersburg, MD, USA). The DNA assay was
processed according to the manufacturer’s instructions, using
microtubes and a water bath for hybridisation and manual
washing. In agreement with the kit manufacturer, clinical speci-
mens were denatured for 90min in order to reduce borderline
results. Relative light units (RLU) were measured on a DML 2000
luminometer (Digene Corporation, Gaithersburg, MD, USA).
Quality control was assessed using the manufacturer’s assay
calibration criteria and by the regular use of HC2 HPV DNA Test
Panel (Digene Corporation, Gaithersburg, MD, USA). The cutoff
value was calculated as the mean RLU value of the calibrator
(1.0pgml
 1 HPV 16 DNA) tested in triplicate. Specimen RLU
values were then converted into a ratio to the cutoff value.
Specimens with a ratio o1.00 were considered negative. Speci-
mens with ratios between 1.00 and 5.00 were systematically
retested in duplicate and the mean of the three values was
calculated. If discrepant RLU values were observed in the two tests,
samples were tested in duplicate again (maximum three thawing
cycles). Specimens with a final ratio X1.00 were considered
positive (HPVþ). In the text, HPV always refers to the Hybrid
Capture
s II test. Therefore, an HPV  might refer to the absence of
HPV virus or to an undetected type by the Hybrid Capture
s II test
or detection of the virus at an RLU ratio o1.00. All positive RLU
values were collected and inserted into the database in order to
compare the viral load expressed in RLU with the cytologic and
biopsy results.
Cytology
All the cytologic slides were read in the Cytopath Laboratory by
one of 13 cytotechnicians who knew which cases in the study but
did not have access to the HPV result (nor did any of the medical
staff) before the cytologic report was sent to the gynaecologist. The
cytologic interpretation was done according to the Bethesda 2001
recommendations (Solomon et al, 2002). Any result XASC-US was
considered as a positive cytologic result (CYTOþ). If either test
was positive, a request was sent for colposcopy with biopsy. To
permit computation of true test sensitivity and specificity, disease
prevalence among the women with both tests negative was assessed
by performing colposcopy and biopsy on 502 randomly selected
members of this group. At the end of the study, all cytologic
preparations associated with a subsequent HSIL biopsy result were
reviewed. The number of positive spots was retrospectively
determined on each slide. A positive spot was defined as a single
cell or a group of cells with sufficient atypia to be reported as at
least an AS-CUS.
Biopsy
Before the beginning of the study, most of the 113 gynaecologists
attended a formal review course on colposcopy procedure and
interpretation taught by a Swiss expert colposcopist and educator.
A biopsy was requested on all patients undergoing colposcopy: the
biopsy would be directed if a lesion was noted (acetowhite
epithelium, mosaicism, etc.), or random by strongly brushing
the proximal endocervical canal if no lesion was visualised. In the
latter case, the collecting device (a brush) was sent to the
laboratory in formalin. At the laboratory, the brush was scraped
with a scalpel and all material was paraffin blocked in order to
obtain a histological preparation.
Statistical methods
Percentage values were described with 95% asymmetrical binomial
confidence intervals computed with the Clopper–Pearson exact
method. Student’s t-test was used to compare mean values with a
threshold of 5% for P-value to be significant. In order to correctly
estimate the sensitivity and specificity of both tests, a method for
correcting biopsy verification bias was used. Verification bias is
caused by the fact that the percentages of biopsy verification vary
considerably among HPV/CYTO subsets because of practical
limitations. Indeed, only 4% (502 out of 12508) of women
HPV /CYTO  and 77% (1031 out of 1334) of women positive for
at least one test, HPVþ/CYTO , HPV /CYTOþ or HPVþ/
CYTOþ, underwent colposcopy with biopsy. Given the low
prevalence of disease in this population, the bias causes a falsely
decreased specificity for both tests. The correction relies on the
estimation of lesion frequency found in each subset HPV/CYTO if
all patients had been colposcoped and biopsied. The adjusted
value (AHCL) was derived from the formula AHCL¼FHCLþUHC
*(FHCL/(FHC(Normal)þFHC(LSIL)þFHC(HSIL))) (Ratnam et al, 2000).
L is the biopsy result. FHCL is the frequency of lesion L obtained
from the study without adjustment within a given HPV/CYTO
subset. UHC is the number of unverified patients in the same subset




In total, 13865 liquid cytology specimens were received in the
laboratory. Of these, 13842 were completed for both tests, CYTO
and HPV. Overall, 9.6% of women (1334 out of 13842) were
positive for one or both tests (CYTO or HPV), 8.2% of women
(1143 out of 13842) were positive for HPV and 6.1% (841 out of
13842) were positive for HPV alone (HPVþCYTO ). In all, 96.4%
(13345 out of 13842) of women were 30 years old or more, with a
percentage of HPV infection of 7.9%. This percentage rose to
17.4% in the 495 women younger than 30 years. For two women,
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ythe age was not available. Mean age of the 13840 women was 44.4
years (range 17–93). The higher frequency of HPV positivity in
younger women is portrayed in Figure 1, where a progressive
decline of HPV positivity is observed as age increases. All further
results are unrelated to age. In total, 3.6% (493 out of 13842) of
women were positive for CYTO and 1.4% (191 out of 13842) were
positive for CYTO alone (HPV CYTOþ). Among the CYTO
results, there were 243 ASC-US (1.8%), 14 atypical squamous cells:
cannot exclude HSIL (ASC-H) (0.1%), 201 low-grade squamous
intraepithelial lesion (LSIL) (1.5%), 30 high-grade squamous
intraepithelial lesion (HSIL) (0.2%) and five atypical glandular
cells (AGC) (0.04%).
Biopsy results
Of the 1334 women with abnormal tests, 1086 (81.4%) underwent
colposcopy with biopsy. Out of 1086, 1031 (95%) biopsies were
satisfactory for evaluation. A total of 18.5% women (248/ out of
1334) refused to be colposcoped, missed appointments or under-
went the follow-up in other laboratories. In order to verify the
negative group (HPV CYTO ), random invitations for colpo-
scopy were regularly sent to women with both tests negative during
the study. Since some women declined to participate, up to 700
invitations were sent before being able to gather the target number
of 500. Finally, 502 women with normal tests were colposcoped and
biopsied. These biopsy results were divided into three categories:
normal, LSIL (CIN 1) and HSIL (CIN2/3). No invasive lesion was
found on cytology and biopsy in any group. The details of the
results are presented in Table 1, where biopsy results are crossed to
CYTO and HPV results. Table 2 presents biopsy results according
to the HPV/CYTO subsets. A key result is that 41.5% of all
histologic HSIL lesions were found in the subset HPVþCYTO .
Sensitivity, specificity and negative predictive value of
CYTO and HPV
The unbiased estimation of frequencies of lesions (normal, LSIL
and HSIL) per HPV/CYTO subset for the entire study population
(Table 3) permits calculation of unbiased sensitivity and specificity
for detection of histologic HSIL (95% confidence interval in
parentheses). Sensitivity is 58.7% (48.6–68.2) for CYTO and 97%
(91.8–99.4) for HPV, while specificity is 96.9% (96.6–97.2) for
CYTO and 92.4% (91.9–92.9) for HPV. The negative predictive
value of CYTO and HPV are, respectively, 99.75 (99.67–99.83) and
99.98 (99.96–100). On the basis of the fact that no histologic HSIL
lesion was found in the 502 randomly chosen women negative for
both tests, the negative predictive value of the combination of
negative tests HPV and CYTO estimated for all 13842 patients is
100% (99.98–100).
Viral load expressed as RLU and logarithm RLU, compared
with cytological and biopsy results
The 1143 HPV-positive results have RLU values ranging from 1 to
3180. The distribution of RLU values is nonlinear. Most RLU
values are small: cumulatively, 22% of all the HPV-positive results
are less than 2.2 RLU, 38% are less than 5.0 RLU and 51% are less
than 11.2 RLU. In order to compare the HPV distribution values
more easily against frequency, the RLU values were transformed
using the natural logarithm function. Therefore, the RLU interval
(1:3200) becomes the lnRLU interval (0:8). The latter was
subdivided in 10 subintervals as illustrated in Figure 2. In this
figure, the black line with small white triangles represents the
percentage of HPVþ samples per lnRLU interval. This line shows
that a majority of HPV-positive samples are associated with low
HPV viral loads. The grey bars in Figure 2 represent the
frequencies of positive CYTO against the HPV viral load expressed
in lnRLU. A clearcut relationship is observed: the CYTO positivity
frequency is directly related to the viral load. In the last subinterval
[7.2–8.0], all the 28 HPVþ samples were always associated with a
positive CYTO test (XASC-US).
The black line with small white squares in Figure 2 represents
the CYTO false negatives with subsequent biopsy proven HSIL.
The 95% confidence intervals are not drawn (to avoid obscuring
the chart) but are enumerated thereafter in square brackets. Per
increasing lnRLU interval, the frequencies of histologic HSIL
(CYTO negative) are 2/5¼40% [12–77], 5/5¼100% [56–100],
5/6¼83% [35–99], 8/10¼80% [44–97], 8/17¼47% [23–72],
6/11¼54% [23–83], 0/9¼0% [0–28], 0/5¼0% [0–45], 0/6¼0%


























Figure 1 Percentage of HPV infection (y-axis) against age intervals (x-axis). 95% confidence intervals are superposed to grey bars. The highest HPV
infection rates are found in the youngest women. The percentage progressively declines as age increases (n¼13840).
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y[0–39] and 0/5¼0% [0–45]. For lnRLU values X4.8, 25 histologic
HSIL were found and all were detected by CYTO.
The black line with small white circles in Figure 2 represents the
CYTO false negatives with subsequent biopsy proven LSIL. The
95% confidence intervals are not drawn as previously, but are
enumerated thereafter in square brackets. Per increasing lnRLU
interval, the frequencies of histologic LSIL (CYTO negative) are
67/79¼84% [75–92], 44/57¼77% [64–87], 34/42¼80% [66–91],
38/47¼80% [67–91], 16/30¼53% [34–72], 16/28¼57% [37–76],
9/19¼47% [24–71], 9/20¼45% [23–68], 7/26¼27% [12–48]
and 0/11¼0% [0–24].
Retrospective analysis of cytological preparations
associated with HSIL
Figure 3 portrays the retrospective analysis of the 79 cytological
preparations (CYTO HPVþ and CYTOþHPVþ) associated
with biopsy-proven HSIL (one cytological preparation,
HPVþCYTOþ, was not available for spot counting). The mean
number of positive spots was 5.2 for HPVþ/CYTO  cytological
preparations (black triangles, n¼34) and 23.1 for HPVþ/
CYTOþ cytological preparations (white squares, n¼45). A total
of 14% (11 out of 79) of cytological preparations HPVþ/CYTO 
did not show any positive spots. The mean lnRLU values were 2.6
for cytological preparations HPVþ/CYTO  (black triangles,
n¼34) and 4.8 for HPVþ/CYTOþ cytological preparations
(white squares, n¼45). Both differences (number of positive spots
and lnRLU) were found significant with t-test (Po0.05). The two
cytological preparations HPV /CYTOþ associated to biopsy-
proven HSIL had six and 10 positive spots (not shown in Figure 3).
DISCUSSION
It is important to note that the methodology of the present study
required that the collecting device be kept in the vial so that 100%
Table 1 Biopsy results (n¼1533) including control group crossed to Pap results (based on Bethesda 2001) and HPV results
PAP cytology results
Biopsy Normal ASC-US ASC-H LSIL HSIL AGC Total
HPV  (n¼626)
AIS 0 0 0 0 0 0 0
CIN3 0 1 0 0 0 0 1
CIN2 0 1 0 0 0 0 1
CIN1 11 39 1 7 0 0 58
Normal 491 63 0 9 1 2 566
Total 502 104 1 16 1 2
HPV+ (n¼907)
AIS* 0 1 0 0 0 2 3
CIN3 25 6 1 7 16 0 55
CIN2 9 2 2 3 6 0 22
CIN1 240 30 1 83 3 0 357
Normal 393 24 1 50 2 0 470
Total 667 63 5 143 27 2
ASC-US¼atypical squamous cells of undetermined significance; ASC-H¼atypical squamous cells: cannot exclude HSIL; LSIL¼low-grade squamous intraepithelial lesion;
HSIL¼high-grade squamous intraepithelial lesion; AGC¼atypical glandular cells. *The three AIS (in situ adenocarcinoma) were found combined with HSIL (CIN3) lesions within
each biopsy.
Table 2 Biopsy results according to subsets HPV/CYTO
Category results Results (n) Satisfactory biopsies (n) Normal biopsies LSIL biopsies HSIL biopsies
HPV CYTO  12508 502 491 (12233.9) 11 (274.1) 0 (0)
HPV CYTO+ 191 124 75 (115.5) 47 (72.4) 2 (3.1)
HPV+CYTO+ 302 240 77 (96.9) 117 (147.2) 46 (57.9)
HPV+CYTO  841 667 393 (495.5) 240 (302.6) 34 (42.9)
Total 13842 1533 1036 (12941.8) 415 (796.3) 82 (103.9)
Adjusted values (AHCL) for verification bias are in parentheses. They derived from the formula AHCL¼FHCL+UHC *(FHCL/(FHC(normal)+FHC(LSIL)+FHC(HSIL))). L is the biopsy result.
FHCL is the frequency of lesion L obtained from the study without adjustment within a given HPV/CYTO subset. UHC is the number of patients in the same subset unverified
either because the biopsy was not received or the biopsy was unsatisfactory. For instance, AHPV+CYTO (normal)¼FHPV+CYTO (normal)+UHPV+CYTO *(FHPV+CYTO (normal)/
(FHPV+CYTO (normal)+FHPV+CYTO (LSIL)+FHPV+CYTO (HSIL)))¼393+(841–667) * (393/(393+240+34))¼495.5 (see text in statistical method for verification bias explanation).
HSIL¼high-grade squamous intraepithelial lesion; LSIL¼low-grade squamous intraepithelial lesion.
Table 3 Frequencies of true positive, true negative, false positive and
false negative for HPV and CYTO tests (for HSIL detection) where HPV
and CYTO represent adjusted values (AHCL, see Table 2 for biopsy
verification bias)
Test frequencies to detect CIN2/3 (HSIL) with related sensitivity and
specificity adjusted with verification bias
Result HPV CYTO
Sensitivity and specificity to
detect HSIL
True positive 100.8 61.0 Sensitivity CYTO 58.7%
True negative 12695.9 13306.1 Specificity CYTO 96.9%
False positive 1042.2 432.0 Sensitivity HPV 97.0%
False negative 3.1 42.9 Specificity HPV 92.4%
95% confidence interval: sensitivity HPV¼[91.8–99.4%], sensitivity CYTO¼[48.6–
68.2%], specificity HPV¼[91.9–92.9%] and specificity CYTO¼[96.6–97.2%].
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Figure 2 Percentage (y-axis) against HPV viral load of 1143 HPVþ samples (x-axis) reported as Logarithm value of Relative Light Unit (LnRLU).
The ‘% women HPVPOS’ curve shows the distribution of the HPVþ samples among LnRLU intervals. In this study, most HPVþ samples have low LnRLU:
near 50% of HPVþ samples are found in the first three LnRLU intervals. The grey bars represent the percentage per LnRLU interval of positive
cytological preparation (XASC-US); it shows a direct relationship between the HPV viral load and the probability for a Pap test to be positive. The HSIL
CYTONEG and LSIL CYTONEG curves represent the percentage per LnRLU interval of false negative cytological preparations with subsequent biopsy
proven lesion.
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Figure 3 Retrospective analysis of all cytological preparations associated with subsequent histological HSIL. Logarithm values of RLU (y-axis) against
number of positive cellular spots (x-axis) retrospectively counted on cytological preparations. False negative CYTO (black triangles) have a smaller viral load
and fewer number of positive cellular spots than true positive CYTO (white squares). Both differences are statistically significant. However, a significant
number of false negative cytological preparations (11 out of 34 (32%)) have no cellular spots despite a significant viral load (n¼79).
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yof the cervical scrape was sent to the laboratory. The conventional
smear, by selecting a random fraction of the cervical scrape,
involves an important loss of material (Goodman and Hutchinson,
1996; Al-Awadhi et al, 2001). LBC technique may also reproduce
the flaws of the conventional smear. It was demonstrated that
when discarding the collecting device, a mean of 37% of the
cervical scrape material is lost. Worse, often the lost material
comes preferentially from the transformation zone (Bigras et al,
2003).
The relationship between the percentage of HPV infection and
the age shown in Figure 1 is similar to those found in other studies
except for the oldest group. This last interval is based on a reduced
number of women as shown by its relatively wide confidence
interval. Furthermore, it is hypothesised that this high frequency is
probably biased because these older women are likely to be those
who had previous abnormal tests and probably form a nonrandom
sample of this age group.
Contribution of HPV viral load study
At the sample level, the study of HPV viral load explains the reason
that CYTO has inferior sensitivity. As shown in Figure 2, the
probability of detecting abnormal cell(s) in an LBC preparation is a
function of the associated HPV viral load. These results are
concordant with the work of Schlecht et al (2003). As HPV is an
intracellular virus, the viral load is proportional to the number of
infected cells. Then, the higher the viral load, the greater the
number of infected cells on the slide and the greater the probability
for the LBC test to be positive. However, the viral load per cell
varies between the LSIL and HSIL cells. LSIL is associated with
active viral genome amplification with up to 1000 viral copies per
keratinocyte (Garner-Hamrick and Fisher, 2002), while HSIL is
associated with host DNA integration with few viral DNA per
keratinocyte (Jeon et al, 1995). Then, an HSIL-associated sample
would contain many more abnormal cells than an LSIL-associated
sample with identical HPV viral load. This would explain why from
4.8 lnRLU value and higher (Figure 2), there are no more histologic
HSIL false negative CYTO samples but still many LSIL false
negative CYTO samples.
While some false negative cytological preparations can be
explained by human misreading, most are not. False negative
preparations would contain few abnormal cells and relatively low
HPV viral load. Inspection of Figure 3 partly supports this
hypothesis. First, it is reasonable, although arbitrary, to accept that
missing up to three abnormal cells among 30000–50000 cells is
independent of cytotechnician reading performance. Therefore,
64% (22 out of 34) of false negative CYTO with subsequent
histologic HSIL were independent of cytotechnician reading
performance. Furthermore, up to 14% (11 out of 79) of cytological
preparations showed no abnormal cells despite relatively high viral
loads. It is then hypothesised that infected cells are present on the
slides but do not always show sufficient morphologic anomalies to
be recognised. This concept is supported in the literature (Ward
et al, 1990; Cramer et al, 1997; Salvia et al, 2004).
At the population level, the study of HPV viral load explains why
cytology sensitivity varies considerably among reports. The
relationship between the probability that a Pap test is abnormal
and the viral load is thought to be independent from intrinsic
factor related to this study. Conversely, the viral load distribution
(Figure 2: black line with white triangles) is unique to the studied
population. Its left-shifted pattern (indicating that a majority of
HPVþ samples have small viral load) would be the hallmark of a
low-risk population. If the same study was repeated with a high-
risk population, it can be expected that the viral load distribution
would be shifted to the right. Then, the number of abnormal cells
per sample would be much more important and, consequently, the
sensitivity gap between HPV and cytology for detection of HSIL
would be much smaller. This idea is supported in the literature, as
studies performed in a high-risk population demonstrated
relatively small gaps (4, 10, 10 and 15%) (Belinson et al, 1999;
Kuhn et al, 2000; Schiffman et al, 2000; Wright et al, 2000)
compared with studies performed in a low-risk population with
higher gaps (30, 38, 54 and 55%) (Ratnam et al, 2000; Clavel et al,
2001; Kulasingam et al, 2002; Petry et al, 2003).
HPV/CYTO subsets
Derived from Table 2, the subsets HPVþ/CYTOþ and HPVþ/
CYTO  represent, respectively, 2.18 and 6.07% of the studied
population. HSIL form 19.2% of biopsies in the HPVþ/CYTOþ
subset and 5.1% in the HPVþ/CYTO  subset. Combining these
results, one computes a ratio women/HSIL of 5.2 for HPVþ/
CYTOþ and 19.6 for HPVþ/CYTO  subsets. The large number
of women without HSIL in the HPVþ/CYTO  subset raises a
difficulty in the clinical management. Wright et al (2004) have
suggested an interim guidance for this issue. They suggested that
colposcopy should not be performed in the setting routinely. HPV,
along with cytology, should be repeated at 6–12 months. If either
test is still positive, then colposcopy should be performed. Finding
rare HSIL in the HPV /CYTOþ subset illustrates that rare HPV
subtypes not detected by HC2 may cause HSIL. Cytology must then
still be part of screening strategy. No HSIL was found in 502
biopsies from the HPV /CYTO  subset. This is concordant with
the Guanacaste study (Bratti et al, 2004: 0 HSIL out of 150) and the
Shanxi study (Belinson et al, 1999 (Dr R Gerald Pretorius, personal
communication, January 2005): 0 HSIL out of 1274). In total, no
HSIL was found in 1926 biopsies from HPV /CYTO  subset. The
95% confidence interval, based on these 1926 biopsies, for the
negative predictive value of the two tests together for histologic
HSIL, is therefore 99.84–100.00%.
CONCLUSIONS
This study found a higher sensitivity for HPV than liquid-based
cytology testing in the detection of cervical cancer precursors. This
adds to previous similar reports with the distinction that our study
involved a nonacademic setting, thereby demonstrating that the
method is robust and readily applicable as a routine test. By
collecting all RLU values, a clearcut correlation between the
probability for a Pap test to be positive and the associated HPV
viral load was found. The findings can also explain how cytology
sensitivity can vary among different studies since different
populations will differ in their viral load distributions: at one
extreme, cytology performs badly when the screened population is
at low –risk, while at the other extreme, cytology performance
would be much closer to that of HPV testing in a high-risk
population. Rare HSIL are not detected by HC2, these cases being
presumably related to HPV types that are not detected by the
cocktail of probes used in HC2. The combination of Pap and HPV
testing identifies all of the women harbouring HSIL that can be
detected by the best colposcopic methods currently available, and
thereby permits investigators and clinicians to focus their efforts
on the population at risk, while reassuring the majority of women
who are negative on both tests.
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